Recro Pharma (REPH) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of Recro Pharma (NASDAQ:REPH) from a hold rating to a buy rating in a research report report published on Wednesday.

A number of other research firms have also weighed in on REPH. Zacks Investment Research raised shares of Recro Pharma from a sell rating to a hold rating in a report on Wednesday, March 21st. Oppenheimer reissued a buy rating on shares of Recro Pharma in a report on Friday, March 23rd. CIBC assumed coverage on shares of Recro Pharma in a report on Wednesday, February 14th. They issued an outperform rating and a $19.00 target price for the company. Finally, UBS started coverage on shares of Recro Pharma in a report on Tuesday, February 13th. They issued an outperform rating for the company. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $14.21.

REPH stock opened at $11.49 on Wednesday. Recro Pharma has a fifty-two week low of $5.81 and a fifty-two week high of $12.23. The company has a quick ratio of 1.55, a current ratio of 1.75 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $224.04, a P/E ratio of -5.77 and a beta of -0.74.

Recro Pharma (NASDAQ:REPH) last posted its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.22. Recro Pharma had a negative net margin of 69.61% and a negative return on equity of 75.97%. The firm had revenue of $19.04 million during the quarter, compared to analyst estimates of $12.88 million. analysts predict that Recro Pharma will post -3.02 earnings per share for the current year.

In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of Recro Pharma stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $10.07, for a total transaction of $2,014,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 21.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in Recro Pharma by 1.4% during the fourth quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock worth $9,359,000 after buying an additional 13,799 shares during the period. Lyon Street Capital LLC bought a new stake in shares of Recro Pharma during the fourth quarter worth $3,362,000. Cadence Capital Management LLC lifted its position in shares of Recro Pharma by 7.8% during the fourth quarter. Cadence Capital Management LLC now owns 180,715 shares of the specialty pharmaceutical company’s stock worth $1,672,000 after purchasing an additional 13,078 shares during the last quarter. State Street Corp bought a new stake in shares of Recro Pharma during the second quarter worth $1,047,000. Finally, Renaissance Technologies LLC lifted its position in shares of Recro Pharma by 23.4% during the fourth quarter. Renaissance Technologies LLC now owns 122,000 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after purchasing an additional 23,100 shares during the last quarter. 56.84% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Recro Pharma (REPH) Rating Increased to Buy at ValuEngine” was originally reported by Ticker Report and is owned by of Ticker Report. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3379316/recro-pharma-reph-rating-increased-to-buy-at-valuengine.html.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analyzing HAVAS  & Publicis Groupe
Analyzing HAVAS & Publicis Groupe
Head-To-Head Review: G-III Apparel Group  & Sequential Brands Group
Head-To-Head Review: G-III Apparel Group & Sequential Brands Group
Builders FirstSource  vs. Floor & Decor  Head-To-Head Survey
Builders FirstSource vs. Floor & Decor Head-To-Head Survey
Brokerages Anticipate LivePerson, Inc.  Will Post Quarterly Sales of $59.47 Million
Brokerages Anticipate LivePerson, Inc. Will Post Quarterly Sales of $59.47 Million
Traders Buy Shares of ConocoPhillips  on Weakness on Insider Selling
Traders Buy Shares of ConocoPhillips on Weakness on Insider Selling
$373.15 Million in Sales Expected for MDC Partners  This Quarter
$373.15 Million in Sales Expected for MDC Partners This Quarter


© 2006-2018 Ticker Report. Google+.